BRAF and thyroid cancer: Ho et al. [29] initially reported that selumetinib increased RAI uptake in five of five participants with NRAS-positive RAI-resistant DTC, compared with four of nine patients with BRAF mutations, suggesting efficacy may be greater in patients with RAS mutant DTC; Cabanillas et al. [30] reported an ORR of 90% in 21 thyroid cancer patients (pooled data from two trials); and most recently Dunn et al. [31] reported that vemurafenib restored RAI uptake and efficacy in four of ten participants with RAI-resistant thyroid cancer.